Promotion of osteoblast differentiation in mesenchymal cells through Cbl-mediated control of STAT5 activity

Stem Cells

Volumn 31, Issue 7, 2013, Pages 1340-1349

  Dieudonne, François Xavier ^a,b   Sévère, Nicolas ^a,b   Biosse Duplan, Martin ^c   Weng, Jing Jie ^d   Su, Yeu ^d   Marie, Pierre J ^a,d  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

c Cbl ubiquitin ligase; Mesenchymal cells; Osteoblast differentiation; RUNX2; STAT5; Ubiquitination

Indexed keywords

ALKALINE PHOSPHATASE; CBL PROTEIN; COLLAGEN TYPE 1; SHORT HAIRPIN RNA; SOMATOMEDIN C; STAT5 PROTEIN; TRANSCRIPTION FACTOR RUNX2; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; NONHUMAN; OSTEOBLAST; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

C-CBL UBIQUITIN LIGASE; MESENCHYMAL CELLS; OSTEOBLAST DIFFERENTIATION; RUNX2; STAT5; UBIQUITINATION;

ANIMALS; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; OSTEOBLASTS; PLURIPOTENT STEM CELLS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; UBIQUITIN-PROTEIN LIGASES;

MURINAE; MUS;

EID: 84879936071     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1380     Document Type: Article

References (62)

1. Aubin JE. Bone stem cells. J Cell Biochem (suppl) 1998;30-31: 73-82.
2. Oyajobi BO, Lomri A, Hott M et al. Isolation and characterization of human clonogenic osteoblast progenitors immunoselected from fetal bone marrow stroma using STRO-1 monoclonal antibody. J Bone Miner Res 1999;14:351-361.
3. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
4. Grove JE, Bruscia E, Krause DS. Plasticity of bone marrow-derived stem cells. Stem Cells 2004;22:487-500.
5. Bianco P, Riminucci M, Gronthos S et al. Bone marrow stromal stem cells: Nature, biology, and potential applications. Stem Cells 2001;19: 180-192.
6. Kassem M. Mesenchymal stem cells: Biological characteristics and potential clinical applications. Cloning Stem Cells 2004;6:369-374.
7. Marie PJ, Fromigue O. Osteogenic differentiation of human marrowderived mesenchymal stem cells. Regen Med 2006;1:539-548.
8. Khosla S, Westendorf JJ, Modder UI. Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells 2010;28:2124-2128.
9. Aubin JE. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001;2:81-94.
10. Lian JB, Javed A, Zaidi SK et al. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004;14:1-41.
11. Karsenty G. Minireview: Transcriptional control of osteoblast differentiation. Endocrinology 2001;142:2731-2733.
12. Lian JB, Stein GS. RUNX2/Cbfa1: A multifunctional regulator of bone formation. Curr Pharm Des 2003;9:2677-2685.
13. Komori T. Signaling networks in RUNX2-dependent bone development. J Cell Biochem 2011;112:750-755.
14. Hassan MQ, Tare RS, Lee SH et al. BMP2 commitment to the osteogenic lineage involves activation of RUNX2 by DLX3 and a homeodomain transcriptional network. J Biol Chem 2006;281:40515-40526.
15. Gaur T, Lengner CJ, Hovhannisyan H et al. Canonical WNT signaling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem 2005;280:33132-33140.
16. Miraoui H, Oudina K, Petite H et al. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/ 2 and protein kinase C signaling. J Biol Chem 2009;284:4897-4904.
17. Zhao Z, Zhao M, Xiao G et al. Gene transfer of the RUNX2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 2005;12:247-253.
18. Dalle Carbonare L, Innamorati G, Valenti MT. Transcription factor RUNX2 and its application to bone tissue engineering. Stem Cell Rev 2012;8:891-897.
19. Ciechanover A. Intracellular protein degradation: From a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture). Angew Chem Int Ed Engl 2005;44:5944-5967.
20. Thien CB, Langdon WY. Cbl: Many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001;2:294-307.
21. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol 2005;6:907-919.
22. Ryan PE, Davies GC, Nau MM et al. Regulating the regulator: Negative regulation of Cbl ubiquitin ligases. Trends Biochem Sci 2006;31: 79-88.
23. Qiang YW, Hu B, Chen Y et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009;113:4319-4330.
24. Yang X, Karsenty G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J Biol Chem 2004;279:47109-47114.
25. Zhao M, Qiao M, Oyajobi BO et al. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/RUNX2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 2003;278: 27939-27944.
26. Glimcher LH, Jones DC, Wein MN. Control of postnatal bone mass by the zinc finger adapter protein Schnurri-3. Ann N Y Acad Sci 2007;1116:174-181.
27. Mukherjee S, Raje N, Schoonmaker JA et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491-504.
28. Sevère N, Dieudonne F-X, Marie PJ. E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis 2013; 4:e463.
29. Miyake S, Lupher ML, Jr., Andoniou CE et al. The Cbl protooncogene product: From an enigmatic oncogene to center stage of signal transduction. Crit Rev Oncog 1997;8:189-218.
30. Thien CB, Langdon WY. EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene. Oncogene 1997;14: 2239-2249.
31. Kassenbrock CK, Anderson SM. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J Biol Chem 2004;279:28017-28027.
32. Swaminathan G, Tsygankov AY. The Cbl family proteins: Ring leaders in regulation of cell signaling. J Cell Physiol 2006;209:21-43.
33. Kaabeche K, Lemonnier J, Le Mee S et al. Cbl-mediated degradation of Lyn and Fyn induced by constitutive FGFR-2 activation supports osteoblast differentiation. J Biol Chem 2004;279:36259-36267.
34. Kaabeche K, Guenou H, Bouvard D et al. Cbl-mediated ubiquitination of alpha5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation. J Cell Sci 2005;118:1223-1232.
35. Guenou H, Kaabeche K, Dufour C et al. Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation. Am J Pathol 2006;169:1303-1311.
36. Dufour C, Guenou H, Kaabeche K et al. FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival. Bone 2008;42:1032-1039.
37. Brennan T, Adapala NS, Barbe MF et al. Abrogation of Cbl-PI3K interaction increases bone formation and osteoblast proliferation. Calcif Tissue Int 2011;89:396-410.
38. Sevère N, Miraoui H, Marie PJ. The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated plateletderived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination. J Biol Chem 2011;286:24443-24450.
39. Gronthos S, Zannettino AC. A method to isolate and purify human bone marrow stromal stem cells. Methods Mol Biol 2008;449:45-57.
40. Ahdjoudj S, Lasmoles F, Oyajobi BO et al. Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotential clonal human marrow stromal F/STRO-1(+) cells. J Cell Biochem 2001;81:23-38.
41. Orosco A, Fromigue O, Bazille C et al. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 2007;67:3708-3715.
42. Chiusaroli R, Sanjay A, Henriksen K et al. Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Dev Biol 2003;261:537-547.
43. Haÿ E, Laplantine E, Geoffroy V et al. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation. Mol Cell Biol 2009;29:953-964.
44. Sevère N, Dieudonne FX, Marty C et al. Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis. J Bone Miner Res 2012;27: 2108-2117.
45. Lian JB, Stein GS, Javed A et al. Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 2006; 7:1-16.
46. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008;22:711-721.
47. Ogawa S, Satake M, Ikuta K. Physical and functional interactions between STAT5 and Runx transcription factors. J Biochem 2008;143: 695-709.
48. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: Lessons learned from STAT5. Cytokine Growth Factor Rev 2004;15:435-455.
49. Mikami Y, Asano M, Honda MJ et al. Bone morphogenetic protein 2 and dexamethasone synergistically increase alkaline phosphatase levels through JAK/STAT signaling in C3H10T1/2 cells. J Cell Physiol 2010;223:123-133.
50. Nicolaidou V, Wong MM, Redpath AN et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. Plos One 2012;7:e39871.
51. DiGirolamo DJ, Mukherjee A, Fulzele K et al. Mode of growth hormone action in osteoblasts. J Biol Chem 2007;282:31666-31674.
52. Eleswarapu S, Ge X, Wang Y et al. Growth hormone-activated STAT5 may indirectly stimulate IGF-I gene transcription through HNF-3{gamma}. Mol Endocrinol 2009;23:2026-2037.
53. Kawai M, Rosen CJ. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem 2012;111:14-19.
54. Desterro JM, Rodriguez MS, Hay RT. Regulation of transcription factors by protein degradation. Cell Mol Life Sci 2000;57:1207-1219.
55. Joung YH, Lim EJ, Darvin P et al. MSM enhances GH signaling via the Jak2/STAT5b pathway in osteoblast-like cells and osteoblast differentiation through the activation of STAT5b in MSCs. Plos One 2012;7:e47477.
56. Salingcarnboriboon RA, Pavasant P, Noda M. Cbl-b enhances RUNX2 protein stability and augments osteocalcin promoter activity in osteoblastic cell lines. J Cell Physiol 2010;224:743-747.
57. Clemens TL, Chernausek SD. Genetic strategies for elucidating insulin- like growth factor action in bone. Growth Horm IGF Res 2004;14: 195-199.
58. Niu T, Rosen CJ. The insulin-like growth factor-I gene and osteoporosis: A critical appraisal. Gene 2005;361:38-56.
59. Gan Y, Zhang Y, Digirolamo DJ et al. Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signaling. Mol Endocrinol 2010;24:644-656.
60. Zhang M, Xuan S, Bouxsein ML et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002;277:44005-44012.
61. Foster LJ, Zeemann PA, Li C et al. Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 2005;23:1367-1377.
62. Qiao M, Shapiro P, Kumar R et al. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem 2004;279:42709-42718.